WEBSITE BSE:506197 NSE: BLISSGVS PH Inc. Year: 1984 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:59
No Notes Added Yet
Bliss GVS Pharma Ltd develops, manufactures, and markets pharmaceutical formulations in India. It gives pharma merchandise, such as drugs, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent capsules, eye/ear drops, injections, liquid arrangements, creams, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, tender gelatin tablets, suppositories, suspensions, syrups, capsules, topical preparation, and transdermal patches. The company additionally gives other healthcare merchandise, consisting ...Read More
Bliss GVS Pharma Ltd develops, manufactures, and markets pharmaceutical formulations in India. It gives pharma merchandise, such as drugs, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent capsules, eye/ear drops, injections, liquid arrangements, creams, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, tender gelatin tablets, suppositories, suspensions, syrups, capsules, topical preparation, and transdermal patches. The company additionally gives other healthcare merchandise, consisting of balms, creams, lozenges, nasal inhalers, lotions, over-the-counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, sprays, syrups, solutions and vaginal washes. In addition, it gives healing products together with anti-bacterial, anti-dandruff shampoo, amino acid training, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile disorder, haematinic, hand sanitizer, health complement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, dietary complement, moisturizer, prickly heat powder, pores and skin lightening lotion, vaginal contraceptive, vaginal hygiene, and nutrition dietary supplements, as well as medicated, complexion, moisturizing, and overall protection soaps. The corporation also exports its merchandise. Bliss GVS Pharma Ltd changed into incorporated in 1984 and is primarily based in Mumbai, India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹2928 Cr.
Stock P/E 32.4
P/B 2.5
Current Price ₹276.8
Book Value ₹ 109.4
Face Value 1
52W High ₹280.2
Dividend Yield 0.18%
52W Low ₹ 105.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 |
| Other Income | 13 | 5 | 6 | 4 | 7 | 15 | 12 | 35 | 20 | 18 |
| Total Income | 224 | 206 | 204 | 188 | 224 | 226 | 210 | 243 | 265 | 237 |
| Total Expenditure | 158 | 157 | 170 | 149 | 178 | 181 | 177 | 166 | 213 | 183 |
| Operating Profit | 67 | 49 | 34 | 38 | 47 | 45 | 33 | 77 | 52 | 53 |
| Interest | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 |
| Depreciation | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 |
| Exceptional Income / Expenses | 0 | 0 | -29 | 0 | 0 | 0 | 0 | 0 | 0 | -3 |
| Profit Before Tax | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 |
| Provision for Tax | 16 | 11 | 1 | 8 | 10 | 11 | 7 | 19 | 12 | 16 |
| Profit After Tax | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 |
| Adjustments | -1 | -1 | -4 | -1 | -1 | -2 | -1 | -1 | -1 | -2 |
| Profit After Adjustments | 42 | 28 | -9 | 21 | 24 | 24 | 16 | 43 | 27 | 23 |
| Adjusted Earnings Per Share | 4.1 | 2.6 | -0.9 | 2 | 2.3 | 2.3 | 1.5 | 4.1 | 2.6 | 2.2 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 867 |
| Other Income | 20 | 24 | 13 | 27 | 38 | 39 | 22 | 31 | 18 | 29 | 36 | 85 |
| Total Income | 427 | 571 | 811 | 841 | 936 | 728 | 599 | 779 | 769 | 799 | 846 | 955 |
| Total Expenditure | 304 | 391 | 596 | 618 | 741 | 566 | 471 | 629 | 634 | 620 | 683 | 739 |
| Operating Profit | 124 | 180 | 215 | 224 | 195 | 163 | 129 | 150 | 135 | 179 | 163 | 215 |
| Interest | 16 | 19 | 20 | 23 | 4 | 8 | 7 | 5 | 10 | 7 | 8 | 11 |
| Depreciation | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 32 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -34 | 0 | -13 | 0 | -74 | 0 | -29 | 0 | -3 |
| Profit Before Tax | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 168 |
| Provision for Tax | 35 | 48 | 63 | 57 | 55 | 34 | 30 | 31 | 29 | 35 | 35 | 54 |
| Profit After Tax | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 115 |
| Adjustments | -1 | -18 | -31 | -30 | -3 | 2 | -5 | -8 | -6 | -6 | -6 | -5 |
| Profit After Adjustments | 60 | 82 | 82 | 59 | 124 | 97 | 68 | 15 | 71 | 75 | 84 | 109 |
| Adjusted Earnings Per Share | 5.8 | 8 | 8 | 5.7 | 12 | 9.4 | 6.6 | 1.5 | 6.8 | 7.2 | 8 | 10.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 5% | 3% | 3% | 7% |
| Operating Profit CAGR | -9% | 3% | 0% | 3% |
| PAT CAGR | 10% | 58% | -1% | 4% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 133% | 53% | 22% | 9% |
| ROE Average | 9% | 9% | 8% | 15% |
| ROCE Average | 12% | 12% | 11% | 19% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 337 | 413 | 487 | 536 | 646 | 736 | 808 | 819 | 884 | 967 | 1050 |
| Minority's Interest | 15 | 33 | 66 | 11 | 14 | 15 | 20 | 28 | 34 | 36 | 41 |
| Borrowings | 57 | 38 | 26 | 6 | 33 | 37 | 33 | 23 | 41 | 36 | 20 |
| Other Non-Current Liabilities | 10 | 11 | 7 | 7 | 5 | 9 | 13 | 6 | 2 | 16 | 17 |
| Total Current Liabilities | 243 | 379 | 437 | 299 | 207 | 231 | 204 | 233 | 193 | 157 | 172 |
| Total Liabilities | 662 | 874 | 1023 | 860 | 905 | 1027 | 1077 | 1109 | 1154 | 1212 | 1301 |
| Fixed Assets | 234 | 225 | 304 | 136 | 145 | 241 | 234 | 281 | 378 | 369 | 405 |
| Other Non-Current Assets | 10 | 66 | 153 | 34 | 66 | 17 | 78 | 51 | 78 | 31 | 69 |
| Total Current Assets | 417 | 583 | 566 | 690 | 693 | 770 | 765 | 777 | 697 | 811 | 819 |
| Total Assets | 662 | 874 | 1023 | 860 | 905 | 1027 | 1077 | 1109 | 1154 | 1212 | 1301 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 39 | 5 | 0 | 47 | 37 | 15 | 15 | 13 | 22 | 25 | 24 |
| Cash Flow from Operating Activities | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 |
| Cash Flow from Investing Activities | -29 | -50 | -231 | 50 | -74 | -48 | -47 | -93 | -8 | -83 | -75 |
| Cash Flow from Financing Activities | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 |
| Net Cash Inflow / Outflow | -33 | 23 | 48 | -8 | -17 | -7 | -4 | 19 | 2 | -1 | 0 |
| Closing Cash & Cash Equivalent | 5 | 28 | 47 | 37 | 15 | 15 | 13 | 22 | 25 | 24 | 24 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.81 | 8 | 7.95 | 5.7 | 11.99 | 9.43 | 6.64 | 1.45 | 6.8 | 7.21 | 8 |
| CEPS(Rs) | 7.05 | 10.99 | 12.88 | 10.67 | 13.15 | 10.46 | 8.84 | 3.9 | 9.16 | 10.31 | 11.36 |
| DPS(Rs) | 0.7 | 0.5 | 0.6 | 1 | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Book NAV/Share(Rs) | 32.64 | 40 | 47.18 | 51.99 | 62.63 | 71.32 | 77.41 | 78.01 | 84.01 | 91.65 | 99.09 |
| Core EBITDA Margin(%) | 25.25 | 28.34 | 25.27 | 24.18 | 17.54 | 17.89 | 18.48 | 15.83 | 15.61 | 19.56 | 15.65 |
| EBIT Margin(%) | 27.45 | 30.36 | 24.32 | 20.62 | 20.74 | 19.81 | 19.29 | 7.88 | 15.49 | 16.07 | 16.52 |
| Pre Tax Margin(%) | 23.44 | 26.97 | 21.86 | 17.82 | 20.24 | 18.71 | 18.04 | 7.25 | 14.11 | 15.17 | 15.52 |
| PAT Margin (%) | 14.99 | 18.22 | 14.04 | 10.88 | 14.1 | 13.82 | 12.82 | 3.09 | 10.21 | 10.59 | 11.15 |
| Cash Profit Margin (%) | 17.75 | 20.64 | 16.55 | 13.5 | 15.09 | 15.64 | 15.8 | 5.41 | 12.69 | 14.02 | 14.78 |
| ROA(%) | 9.01 | 13.04 | 11.88 | 9.42 | 14.35 | 9.86 | 7.03 | 2.12 | 6.78 | 6.9 | 7.18 |
| ROE(%) | 19.74 | 26.73 | 25.06 | 17.34 | 21.43 | 13.79 | 9.64 | 2.88 | 9.11 | 8.89 | 9.01 |
| ROCE(%) | 23.57 | 32.07 | 31.06 | 24.61 | 26.58 | 17.02 | 12.49 | 6.37 | 12.22 | 12.15 | 12.29 |
| Receivable days | 206.07 | 182.13 | 126.33 | 123.8 | 154.2 | 267.05 | 319.89 | 209.14 | 188.89 | 187.07 | 189.93 |
| Inventory Days | 29.51 | 24.04 | 20.01 | 24.25 | 27.7 | 40.11 | 54.72 | 54.42 | 55.12 | 52.48 | 55.03 |
| Payable days | 194.35 | 145.29 | 105.12 | 73.11 | 40.93 | 70.02 | 90.85 | 77.87 | 81.4 | 70.38 | 58.4 |
| PER(x) | 22.21 | 15.86 | 22.18 | 34.28 | 15 | 10.69 | 14.86 | 53.04 | 10.47 | 15.63 | 14.69 |
| Price/Book(x) | 3.95 | 3.17 | 3.74 | 3.76 | 2.87 | 1.41 | 1.28 | 0.99 | 0.85 | 1.23 | 1.19 |
| Dividend Yield(%) | 0.54 | 0.39 | 0.34 | 0.51 | 0.56 | 0.5 | 0.51 | 0.65 | 0.7 | 0.44 | 0.43 |
| EV/Net Sales(x) | 3.52 | 2.49 | 2.37 | 2.51 | 2.06 | 1.53 | 1.72 | 0.97 | 0.98 | 1.37 | 1.35 |
| EV/Core EBITDA(x) | 11.58 | 7.56 | 8.8 | 9.14 | 9.48 | 6.51 | 7.72 | 4.84 | 5.46 | 5.86 | 6.72 |
| Net Sales Growth(%) | 18.13 | 34.33 | 45.99 | 2.03 | 10.3 | -23.29 | -16.26 | 29.5 | 0.55 | 2.48 | 5.13 |
| EBIT Growth(%) | 26.98 | 48.37 | 16.96 | -13.84 | 10.85 | -26.72 | -18.43 | -47.11 | 97.66 | 6.31 | 8.06 |
| PAT Growth(%) | 49.63 | 63.12 | 12.52 | -21.32 | 42.86 | -24.8 | -22.34 | -68.74 | 231.8 | 6.31 | 10.64 |
| EPS Growth(%) | 46.15 | 37.68 | -0.53 | -28.35 | 110.46 | -21.38 | -29.58 | -78.15 | 368.97 | 5.94 | 11 |
| Debt/Equity(x) | 0.47 | 0.32 | 0.46 | 0.22 | 0.16 | 0.16 | 0.15 | 0.13 | 0.11 | 0.09 | 0.07 |
| Current Ratio(x) | 1.72 | 1.54 | 1.29 | 2.3 | 3.35 | 3.34 | 3.76 | 3.33 | 3.61 | 5.15 | 4.77 |
| Quick Ratio(x) | 1.58 | 1.44 | 1.18 | 2.11 | 2.98 | 3.02 | 3.27 | 2.8 | 3.08 | 4.4 | 4.04 |
| Interest Cover(x) | 6.85 | 8.96 | 9.91 | 7.37 | 42.21 | 18.04 | 15.38 | 12.42 | 11.23 | 17.91 | 16.47 |
| Total Debt/Mcap(x) | 0.12 | 0.1 | 0.12 | 0.06 | 0.05 | 0.12 | 0.12 | 0.13 | 0.13 | 0.07 | 0.06 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 34.97 | 34.97 | 34.9 | 34.82 | 35.1 | 35.29 | 35.44 | 35.39 | 35.36 | 35.36 |
| FII | 15.35 | 14.73 | 13.25 | 12.13 | 13.51 | 13.18 | 12.65 | 13.27 | 14.54 | 10.45 |
| DII | 6.61 | 6.59 | 6.58 | 6.57 | 6.55 | 6.55 | 6.54 | 5.98 | 5.78 | 5.04 |
| Public | 43.08 | 43.71 | 45.27 | 46.49 | 44.84 | 44.98 | 45.36 | 45.36 | 44.32 | 49.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.66 | 3.66 | 3.66 | 3.66 | 3.7 | 3.72 | 3.74 | 3.74 | 3.74 | 3.74 |
| FII | 1.61 | 1.54 | 1.39 | 1.28 | 1.42 | 1.39 | 1.33 | 1.4 | 1.54 | 1.11 |
| DII | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.63 | 0.61 | 0.53 |
| Public | 4.51 | 4.58 | 4.75 | 4.89 | 4.72 | 4.74 | 4.79 | 4.79 | 4.69 | 5.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.47 | 10.47 | 10.49 | 10.51 | 10.54 | 10.54 | 10.55 | 10.56 | 10.58 | 10.58 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
